Nutex Health is trading 11.02% up now at $168.52 after its August 6, 2026, second-quarter results showed $9.38 diluted EPS versus approximately $4.88 expected.
- Attributable net income was $65.8 million, supported largely by a $52.3 million reduction in arbitration-related expenses following the HaloMD amendment and lower federal IDR fees.
- Revenue declined 13.6% year over year to $210.8 million, while full-year guidance remained reaffirmed.